netarsudil ophthalmic solution 0.02%

Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Aerieā€™s focus on therapies that address cause of vision lossAerie Pharmaceuticals is developing the first novel mechanism of action for the treatment of glaucoma in over 20 years. The company is developing two products for the treatment of patients with glaucoma and ocular hypertension. One is an entirely new agent, netarsudil, the other is a combination of netarsudil plus latanoprost.
Novel ocular hypotensive drug meets endpointsNetarsudil ophthalmic solution 0.02% met its primary and secondary efficacy endpoints in a third phase III trial investigating its non-inferiority to timolol maleate 0.05% for IOP lowering.
Rocket 2 meets safety endpoints for netarsudilNetarsudil ophthalmic solution 0.02% q.d. maintained consistent IOP-lowering efficacy through 12 months for the Rocket 2 trial.